Advertisement
Canada markets closed

  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     

  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • CAD/USD

    0.7235
    -0.0019 (-0.26%)
     

  • CRUDE OIL

    85.31
    -0.05 (-0.06%)
     

  • Bitcoin CAD

    88,351.77
    +1,015.34 (+1.16%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,399.50
    -8.30 (-0.34%)
     

  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • NASDAQ futures

    17,894.00
    +17.75 (+0.10%)
     

  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6812
    -0.0012 (-0.18%)
     
BREAKING:

$535B CANADA BUDGET PROJECTS $39.8B DEFICIT, AIMS TO RESTORE ECONOMIC FAIRNESS

It seeks to ease the housing and affordability crisis by making older, wealthier Canadians pay more

ZSAN DEADLINE NOTICE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN

Zhang Investor Law P.C.
·2 min read

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=zosano-pharma-corporation&id=2478 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=zosano-pharma-corporation&id=2478

If you wish to serve as lead plaintiff, you must move the Court before the December 28, DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

ADVERTISEMENT

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (a) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (b) pharmocokinetic studies submitted in connection with the Company’s New Drug Application (“NDA”) included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (c) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require further studies to support regulatory approval of Qtrypta; (d) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (e) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
info@zhanginvestorlaw.com
tel: (800) 991-3756